Glenmark Pharmaceuticals Ltd – From Generics to Billion-Dollar AbbVie Deals, This Script is Finally Acting Like a Blockbuster
1. At a Glance
Once known only as a generic drug factory, Glenmark just pulled off a $700M upfront licensing jackpot with AbbVie and is running Phase 3 cancer trials like it’s Netflix greenlighting new series. But behind the glamour lies the classic pharma drama—FDA warning letters, patchy US generics, and sales growth slower than Mumbai traffic. Still, with an ROCE of 19.4% and a market cap of ₹60,000 Cr, Glenmark seems to have traded its small-cap soap opera vibes for a proper multiplex release.
2. Introduction
Picture Glenmark in the early 2000s: hustling to make generics, trying to crack the US market, and fighting lawsuits like a daily gym routine. Fast-forward to 2025, and the company is juggling three avatars:
Generics for steady cash flows,
Specialty drugs like Ryaltris (for allergies) expanding across 70+ countries,
Innovation via Ichnos Sciences, its US subsidiary chasing immuno-oncology moonshots.
They’ve got presence in 80+ countries, 14 factories (11 in India, 8 USFDA-approved), and over 1,400 R&D soldiers grinding in labs. Yet, despite the science flex, their sales CAGR over 5 years is barely 5%. Clearly, science moves faster than the stock.
But then came the AbbVie deal—a licensing arrangement for ISB 2001, an oncology asset. $700M upfront, $1.2B more in milestones. Suddenly, Glenmark isn’t the struggler in the Nifty Pharma cast; it’s auditioning for lead roles.
3. Business Model – WTF Do They Even Do?
Glenmark’s business is like a Bollywood masala mix—something for everyone:
India (25% revenue): Respiratory, dermatology, and cardiac therapies. Glenmark is #2 in both respiratory and dermatology segments.
North America (24%): Generics + injectables. Recently restarted Monroe site injectables; filings for complex inhalers (gFlovent, generic pMDIs) are lined up.
Europe (18%): UK, Spain, Germany driving growth, with Ryaltris and asthma brands holding fort.
ROW (21%): LatAm, MEA, Russia, and Asia, with respiratory launches as growth drivers.
API (12%): Backward integration muscle.
And then there’s Ichnos Sciences, the loss-making but potentially jackpot-creating arm in the US, now wrapped into Ichnos Glenmark Innovation. They’re testing oncology molecules for multiple myeloma, AML, and solid tumors—with two orphan drug designations in the US.
In short, Glenmark is trying to balance boring-but-stable generics with high-stakes biotech poker.
4. Financials Overview
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
3,264 Cr
3,244 Cr
3,256 Cr
0.6%
0.2%
EBITDA
581 Cr
588 Cr
561 Cr
-1.2%
3.6%
PAT
260 Cr
340 Cr
47 Cr
-23.5%
453%
EPS (₹)
9.2 (Ann.)
12.1
1.7
-24%
Massive turnaround
Commentary: Revenue flat, margins steady, profit volatile. Basically, quarterly numbers look like your gym attendance—some months great, some months missing in action.
👉 Fair Value Range: ₹1,000 – ₹1,250/share Disclaimer: This range is for educational purposes only. No, SEBI won’t let me sell you stocks through stand-up comedy.
6. What’s Cooking – News, Triggers, Drama
AbbVie Deal (Sept’25): $700M upfront for ISB 2001 licensing, plus $1.2B milestones. Biggest licensing payday for Glenmark ever.
Oncology Pipeline: Envafolimab Phase 3 in NSCLC, Brukinsa launch in India, Tevimbra rolled out for lung &
